Introduction

Cystic Fibrosis is the most common life-shortening genetic disease and is carried as an autosomal recessive trait by about 3% of the white population. The average age of survival is continually increasing and is now above 30 resulting in adult management issues and required changes for long-term treatment strategies. 

Scope

Information on the prevalence and epidemiology is provided for the seven major world markets 

Current therapies including gold standards and alternative treatments 

Adult management of cystic fibrosis as an increasingly important issue. Current monitoring methods, treatments and industry institutional suggestions 

Information on current late phase trials and analysis against gold standard treatments 

Report Highlights

Current therapies focus on the treatment of lung infections and pancreatic insufficiency. Emerging and existing bacterial infections continue to be the leading cause of death in Cystic Fibrosis patients with Pseudomonas aeruginosa colonizing 80% of sufferers by the age of 18. 

Cystic Fibrosis lacks any novel pipeline therapies in late phase trials. The therapy with the most ‘blockbuster’ potential is a gene therapy targeting Cystic Fibrosis - tgAAVCF. It is in the later stage of phase II trials and is the first gene therapy to exhibit such promising efficacy results. 

Reasons to Purchase

Product evaluation – Benchmarking of selected pipeline candidates against gold standard treatments 

Market changes - Strengthen market knowledge in key trends and changing epidemiology 

Business development – Identify in-licensing and out-licensing opportunities 

Publisher: Datamonitor Respiratory Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Respiratory.html#a380